CTKB
Cytek Biosciences, Inc.
CTKB's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CTKB overall, supported by lower modeled downside and stronger modeled upside.
CTKB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
CTKB's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CTKB PE Valuation
CTKB has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CTKB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
CTKB has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CTKB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.54 |
| Q2 2026 | -$0.63 | -$0.58 |
| Q1 2026 | -$0.58 | -$0.49 |
| Q4 2025 | -$0.52 | -$0.47 |
| Q3 2025 | -$0.10 | -$0.02 |
| Q2 2025 | -$0.05 | +$0.09 |
| Q1 2025 | -$0.09 | $0.00 |
| Q4 2024 | -$0.05 | +$0.04 |
CTKB lost $0.64 per share over the past year, and its loss has widened in each of the last five quarters.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CTKB on earnings quality, reporting a profit while its opponent remains loss making.
CTKB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.2M | +1.8% |
| Q2 2026 | $48.1M | +5.6% |
| Q1 2026 | $44.1M | +6.5% |
| Q4 2025 | $62.1M | +8.1% |
| Q3 2025 | $52.3M | +1.5% |
| Q2 2025 | $45.6M | -2.2% |
| Q1 2025 | $41.5M | -7.6% |
| Q4 2024 | $57.5M | -1.3% |
CTKB's revenue has grown year over year for five quarters in a row: $53M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +1.8 points |
| Q2 2026 | -24% | -0.4 points |
| Q1 2026 | -42% | -5.7 points |
| Q4 2025 | -9% | -14 points |
| Q3 2025 | -18% | -9.3 points |
| Q2 2025 | -23% | -5 points |
| Q1 2025 | -36% | -12 points |
| Q4 2024 | 5.2% | +5.4 points |
CTKB's operating margin was −16% last quarter, up 1.8 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CTKB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CTKB on profitability, with a higher operating margin.
CTKB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6M | -$1.4M |
| Q2 2026 | -$849K | +$620K |
| Q1 2026 | -$4.9M | -$3.9M |
| Q4 2025 | -$1.8M | -261% |
| Q3 2025 | -$4.6M | -137% |
| Q2 2025 | -$1.5M | -129% |
| Q1 2025 | -$974K | -129% |
| Q4 2024 | $1.1M | -86% |
CTKB has burned cash in seven of the last eight quarters: −$13M over the past year, against −$6M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CTKB on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTKB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +898K shares |
| 1 year | +2.2% | +2.8M shares |
| 3 years | -4.3% | -5.8M shares |
| 5 years | +260% | +94.2M shares |
| Available history | +6% | +7.3M shares |
CTKB has 130M diluted shares, up 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $34,000 |
| Q3 2025 | $29,000 |
| Q2 2025 | $4.5M |
| Q1 2025 | $10.6M |
| Q4 2024 | $7M |
CTKB has spent almost nothing on buybacks in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CTKB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CTKB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -431.1x | Net Cash |
| Q3 2022 | -185.1x | Net Cash |
| Q2 2022 | -100.0x | Net Cash |
| Q1 2022 | -48.1x | Net Cash |
| Q4 2021 | -37.2x | Net Cash |
| Q3 2021 | -23.1x | Net Cash |
| Q2 2021 | -7.9x | Net Cash |
| Q1 2021 | -10.0x | Net Cash |
CTKB has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CTKB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.6 | Neutral |
| Stochastic | 77.2 | Neutral |
CTKB's weekly RSI is 57 (neutral) and its Stochastic is 77 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CTKB PE vs Healthcare Sector
| Metric | CTKB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTKB has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CTKB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 2.5% below |
| 20 week MA | $5.04 | 9.5% above |
| 50 week MA | $4.73 | 17% above |
| 100 week MA | $4.50 | 23% above |
| 200 week MA | $5.95 | 7.2% below |
CTKB's trend is mixed: it's above three of its five weekly moving averages, and 7.2% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CTKB on trend strength, trading above more of its moving averages.
CTKB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.8 | $17.3 | -8% |
| 2022 | $17.3 | $10.1 | -41% |
| 2023 | $10.1 | $9.12 | -9.9% |
| 2024 | $9.12 | $6.39 | -30% |
| 2025 | $6.39 | $5.10 | -20% |
| 2026 YTD | $5.10 | $5.52 | +8.2% |
CTKB has finished every year since 2021 lower, and it's up 8.2% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CTKB on returns for 2026, with the stronger performance.